肝脏小血管肿瘤在18F-DCFPyl PET/CT上模拟前列腺癌
18F-DCFPyl是一种靶向前列腺特异性膜抗原的放射性示踪剂,用于检测复发或转移性前列腺癌。随着使用增多,越来越多非前列腺疾病被识别出可表达前列腺特异性膜抗原并模拟前列腺癌。本文描述一例与肝脏小血管肿瘤相关的18F-DCFPyl摄取,该关联此前文献未见报道。
要点
- 18F-DCFPyl靶向前列腺特异性膜抗原,用于检测复发或转移性前列腺癌。
- 非前列腺疾病可表达前列腺特异性膜抗原并模拟前列腺癌。
- 本文报道肝脏小血管肿瘤相关的18F-DCFPyl摄取,此前未见文献描述。
核心结论
- 肝脏小血管肿瘤可表现为18F-DCFPyl摄取,可能模拟前列腺癌,该关联此前文献未见报道。
研究设计与样本
- 本文为病例报告,描述一例与肝脏小血管肿瘤相关的18F-DCFPyl PET/CT摄取表现。
主要发现
- 18F-DCFPyl PET/CT显示与肝脏小血管肿瘤相关的放射性示踪剂摄取。
临床怎么用
- 阅片医师应结合血清前列腺特异性抗原水平和摄取分布等其他变量,避免不恰当诊断转移性前列腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18 F-DCFPyl is a Food and Drug Administration-approved radiotracer that targets prostate-specific membrane antigen and is used in the detection of recurrent or metastatic prostate cancer. As its use has increased, a growing number of nonprostatic disease entities have been identified that express prostate-specific membrane antigen and can mimic prostate cancer. Thus, the interpreting physician must also consider other variables such as serum prostate-specific antigen levels and the distribution of uptake to avoid an inappropriate diagnosis of metastatic prostate cancer. We describe 18 F-DCFPyl uptake associated with a hepatic small vessel neoplasm, an association previously undescribed in the literature.
引用
- Spinali KL, Papke DJ, Shah HJ, et al. Hepatic Small Vessel Neoplasm Mimics Prostate Cancer on 18 F-DCFPyl PET/CT. Clin Nucl Med. 2023. PMID: 36728165. doi:10.1097/RLU.0000000000004554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。